Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

NCT ID: NCT00606814

Last Updated: 2012-03-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-31
• Study Completion Date: 2011-12-31

Brief Summary

This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine:

• the safety profile,
• the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and
• to recommend a Phase II dose of the combination in patients with solid tumors.

Detailed Description

IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in maintaining the proper folding, function and viability of various "client proteins". Many of the client proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival.

This is a multi-center, open-label, dose escalating study in which patients will be treated with a fixed dose of docetaxel followed by IPI-504 following one of three dosing schedules.

Once an MTD has been defined, up to 20 additional patients with non-small cell lung cancer (NSCLC) will be enrolled.

Conditions

Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

IPI-504, docetaxel

1. IPI-504 administered IV at a dose of 300mg/m2

2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration

Intervention Type: DRUG

Other Intervention Names

Taxotere

Eligibility Criteria

Inclusion Criteria

• Pathologically confirmed malignancy that is metastatic or unresectable, for which one of the two statements must apply:

• Standard therapy able to provide clinical benefit does not exist or is no longer effective AND / OR
• Single agent docetaxel would be appropriate therapy.
• Progressive disease with development of new lesions or an increase in preexisting lesions on CT, MRI, PET, bone scintigraphy, or by physical examination.
• Measurable disease by RECIST criteria with the exception of prostate cancer patients.
• >18 years of age at the time of signing the Informed Consent Form (ICF) and have a life expectancy of at least 3 months.
• Karnofsky performance status of 70 or better.
• Adhere to the study visit schedule
• Voluntarily sign the Informed Consent Form (ICF).
• Baseline studies completed within 30 days of first study dose.
• Women of child-bearing potential (WCBP) defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months must have a negative serum or urine pregnancy test within 2 weeks of first study dose and prior to each additional cycle of treatment.
• All WCBP and all sexually active male patients must agree to use adequate methods of birth control throughout the study

• Must have archival NSCLC tissue available for submission and analysis.

Exclusion Criteria

• Treatment within 1 week of the start of IPI-504 for erlotinib, and imatinib; within 2 weeks for gefitinib, and any other tyrosine kinase inhibitor (approved or investigational); within 4 weeks for any biologic therapy (antibody, vaccine, or other protein-based therapy), radiation therapy, or conventional chemotherapy; within 6 weeks for nitrosoureas or mitomycin C.
• Radiation therapy within 2 weeks of the start of IPI-504. (Patients must have recovered from any toxicities.)
• Concurrent radiation therapy or treatment with any other investigational agent is not permitted.
• Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to Cycle 1, Dose 1.
• Symptomatic peripheral neuropathy ≥ Grade 2.
• Inadequate hematologic function defined by absolute neutrophil count (ANC) <1,500 cells/mm3, a platelet count <100,000/mm3, and a hemoglobin <9.0 g/dL (may be increased to this level with transfusion as long as there is no evidence of active bleeding).
• Inadequate renal function defined by AST and/or ALT >1.5; total bilirubin above the upper limit of normal.
• Inadequate renal function defined by serum creatinine >1.5 x ULN.
• Sinus bradycardia (resting heart rate <50) secondary to intrinsic conduction system disease. Patients with sinus bradycardia secondary to pharmacologic treatment may enroll if withdrawal of the treatment results in normalization of the resting heart rate to within normal limits.
• Baseline QTc >450 msec in males; QTc >470 msec in females, or previous history of QT prolongation while taking other medications.
• Presence of left bundle branch block, right bundle branch block plus left anterior hemiblock, bifasicular block or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.
• Patients who have received >450 mg/m2 of any anthracycline during prior chemotherapy must have a baseline LVEF >40%.
• Active keratitis or keratoconjunctivitis.
• History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
• Presence of active infection or systemic use of antibiotics within 72 hours of treatment.
• Untreated brain metastases. Note: Patients with a history of brain metastases are eligible as long as definitive treatment has been given and patients are clinically stable.
• Significant co-morbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study (e.g., cardiac disease such as acute coronary syndrome or unstable angina within 6 months, uncontrolled hypertension, arrhythmia requiring medication or mechanical control, cirrhotic liver disease, or other conditions).
• Previous or current malignancies at other sites within the last 2 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
• HIV-positive patients receiving combination antiretroviral therapy.
• Women who are pregnant or lactating.
• Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor.
• Patients with prior hepatic resection or hepatic-directed therapy (e.g., chemoembolization or Theresphere).

• Prior treatment with docetaxel
• Three or more chemotherapy regimens for metastatic disease. Note: Any number of prior treatment regimens with tyrosine kinase inhibitors is permitted.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Infinity Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gregory Riely, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

TGen Clinical Research in Scottsdale

Scottsdale, Arizona, United States

Yale Cancer Center

New Haven, Connecticut, United States

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Gabrail Cancer Center

Canton, Ohio, United States

Gabrail Cancer Center

Dover, Ohio, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Countries

United States

Other Identifiers

IPI-504-05

Identifier Type: -

Identifier Source: secondary_id

IPI-504-05

Identifier Type: -

Identifier Source: org_study_id